Not exact matches
Then, to boost the number of cells, which is another hurdle in tissue engineering, the researchers mixed the chondrocytes
with human mesenchymal stem cells from
bone marrow.
In
humans, a comparison of
bone marrow from 14 normal
bone marrow donors, 35 multiple myeloma patients and 11 patients
with a noncancerous condition called monoclonal gammopathy of undetermined significance (MGUS) showed that Runx2 levels were significantly higher in the multiple myeloma cells.
Tufts University biomedical engineers recently published the first report of a promising new way to induce
human mesenchymal stem cells (or hMSCs, which are derived from
bone marrow) to differentiate into neuron - like cells: treating them
with exosomes.
The researchers used «humanized mice,» which have had their immune systems replaced
with human immune system cells, thymus tissue and
bone marrow.
Subsequent transplant of millions of
human T - ALL cells into normal mice that were then treated
with an anti-CXCR4 drug induced remission within two weeks,
with diseased spleen and
bone marrow tissue nearly returning to normal.
Prior research
with cultured tissue had shown that a mix of chemicals could change
bone marrow stem cells from mice to those resembling brain cells, but when a team led by neurologist Lorraine Iacovitti of Thomas Jefferson University in Philadelphia tried the same brew on
human cells, the number altered was modest.
She ultimately chose to study leukemia patients» immune responses to
bone marrow transplants, an area conducive to translational research in part because the work involves treating patients
with human cells, which can be prepared at academic health centers.
David Kaplan, Ph.D., professor and Director of the NIH P41 Resource Center on Tissue Engineering, Alessandra Balduini, M.D., and their collaborators have focused on forming
bone marrow models
with these components and other growth factors to imitate and support the formation of functional
human platelets.
Human bone marrow (BM)- derived progenitor and stem cells administered
with an appropriate scaffold represents a potentially exciting alternative treatment option [2], but only if we can discover a safe and rapid strategy to enhance the relatively low inherent osteogenic potential of BM.
In close collaboration
with universities and physicians world - wide, our comprehensive investigational stem cell treatments employ well - targeted combinations of allogeneic
human umbilical cord stem cells, autologous
bone marrow stem cells, and autologous adipose stem cells for the diseases listed below.
In separate experiments reported in Nature — one
with mice, the other transplanting
human stem cells into mouse
bone marrow — researchers demonstrated techniques
with the potential to produce all types of blood cells.
The study assessed safety and efficacy of intracoronary autologous transplantation of
bone marrow - derived
human MSCs in patients
with acute myocardial infarction.
The stem cell therapy done is from your own
bone marrow and hence acceptability of the
human body is more
with no adverse effects
Patients receive one of two types of stem cell - based transplants: autologous, in which a patient donates and receives back his / her own stem cells; or allogeneic, in which
bone marrow - derived stem cells come from a related or unrelated donor whose
human leukocyte antigens (HLA) are genetically matched
with those of a patient.
In the recent study, the researchers used CRISPR snipped out the sickle cell mutation from donated
human bone marrow cells, and replaced it
with non-mutated DNA.
Using primary murine
bone marrow derived macrophages or
human monocyte derived dendritic cells, infected
with live or attenuated Chlamydia trachomatis we report that the live organism activates both canonical and non-canonical inflammasomes, but only canonical inflammasomes controlled IL - 1β processing which preceded pyroptosis.